Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations
Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations: A Prospective, Multi-center, Randomized, Parallel Positive Controlled, Non-inferiority Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jing Pan
- Phone Number: 18916099975
- Email: jing.pan@ton-bridge.com
Study Contact Backup
- Name: Jin Zheng
Study Locations
-
-
-
Beijing, China
- Xuanwu Hospital Capital Medical University
-
Contact:
- Peng Zhang
-
Chengdu, China
- Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital
-
Principal Investigator:
- Tian Zhang
-
Guangzhou, China
- Guangdong Provincial People's Hospital
-
Principal Investigator:
- Guangzhong Chen
-
Hefei, China
- Anhui Provincial Hospital
-
Principal Investigator:
- Ge Gao
-
Jining, China
- Jining No.1 People's Hospital
-
Principal Investigator:
- Feng Lei
-
Wuhan, China
- Tongji Hospital Tongji Medical College Of Hust
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Nanfang Hospital Southern Medical University
-
Guangzhou, Guangdong, China
- ZhuJiang Hospital of Southern Medical University
-
-
Henan
-
Zhengzhou, Henan, China
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou, Henan, China
- Henan Provincial People's Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- General Hospital of Eastern Theater Command
-
-
Jilin
-
Changchun, Jilin, China
- The First Hospital of Jilin University
-
-
Liaoning
-
Shenyang, Liaoning, China
- General Hospital of Northern Theater Command
-
-
Shandong
-
Jinan, Shandong, China
- Qilu Hospital of Shandong University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 to 80 years, any gender;
- Subject is suitable for endovascular treatment of cerebrovascular malformations;
- Subject is able to understand the purpose of the study, shows sufficient compliance with the study protocol and provides a signed informed consent form.
Exclusion Criteria:
- Intracranial hemorrhage within 1 month prior to treatment;
- The targeted embolization area needs to receive other treatments (surgical resection, SRS, other embolic materials) at the same time;
- Combination of other cerebrovascular malformations, such as cavernous vascular malformation;
- Severe stenosis or occlusion of cerebral feeding artery requiring surgical intervention;
- Intracranial tumor requiring surgical intervention;
- mRS score≥3;
- Heart, lung, liver and renal failure or other severe diseases;
- Known bleeding tendency, such as coagulation dysfunction (INR>1.5);
- Known allergy to DMSO and contrast media, or contraindication to anticoagulant therapy;
- Pregnant or breastfeeding women, or who plan to become pregnant during the study;
- Subject is participating in other drug or medical device clinical trials at the time of signing informed consent;
- Other conditions judged by the investigators as unsuitable for enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Liquid Embolic System (Tonbridge)
|
Endovascular treatment with Liquid Embolic System (Tonbridge).
|
|
Active Comparator: Onyx Liquid Embolic System (Medtronic)
|
Endovascular treatment with Onyx Liquid Embolic System (Medtronic).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Targeted Embolization Satisfaction Rate
Time Frame: intra-procedure
|
Targeted embolization satisfaction is defined as achieving ≥50% occlusion of the targeted embolized area after treatment with liquid embolic system, which is determined by immediate postoperative cerebrovascular DSA.
|
intra-procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mRS score
Time Frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
|
mRS scores are assessed at each evaluation time point.
|
1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
|
|
GOS score
Time Frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
|
GOS scores are assessed at each evaluation time point.
|
1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
|
|
Operation satisfaction rate
Time Frame: intra-procedure
|
The 5-point Likert scale is used to evaluate operation satisfaction from three aspects: visualization, diffusion, and microcatheter withdrawal.
"Operation satisfaction rate" is defined as the proportion of investigational devices or comparators with Likert score≥12 points.
|
intra-procedure
|
|
Incidence of major adverse events (MAEs)
Time Frame: 1 month±7 days, 3 months±30 days post-procedure
|
MAEs are defined as intracranial hemorrhage and ischemic complications.
Intracranial hemorrhage included intraoperative hemorrhage (puncture of blood-supplying arteries by catheters or guidewires, rupture of nidus, and injury to blood vessels during withdrawal of catheters) and delayed symptomatic hemorrhage in the postoperative period; and ischemic complications included intraoperative ischemic complications (displacement of liquid embolic agents, thrombosis, and so on) and postoperative symptomatic ischemic stroke.
"Incidence of major adverse events" is the proportion of subjects with adverse events using the investigational device or the comparator.
|
1 month±7 days, 3 months±30 days post-procedure
|
|
Incidence of adverse events (AEs)
Time Frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
|
"Incidence of adverse events" is the proportion of subjects with adverse events using the investigational device or the comparator.
|
1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
|
|
Incidence of serious adverse events (SAEs)
Time Frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
|
"Incidence of serious adverse events" is the proportion of subjects with serious adverse events using the investigational device or the comparator.
|
1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
|
|
Incidence of device deficiency
Time Frame: 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
|
Device deficiency is the unreasonable risk that may endanger human health and life safety in the normal use of medical devices during clinical trials, such as labeling errors, quality problems and malfunctions.
|
3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Peng Zhang, Xuanwu Hospital, Beijing
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Cardiovascular Abnormalities
- Nervous System Malformations
- Vascular Malformations
- Intracranial Arterial Diseases
- Central Nervous System Vascular Malformations
- Congenital Abnormalities
- Arteriovenous Malformations
- Intracranial Arteriovenous Malformations
Other Study ID Numbers
Other Study ID Numbers
- SZTQ202401
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.